Inhibition of human pancreatic cell line MIA PaCa2 proliferation by HA-but, a hyaluronic butyric ester: A preliminary report

Pancreas

Volumn 36, Issue 4, 2008, Pages

  Pellizzaro, Cinzia ^a   Speranza, Annalisa ^a   Zorzet, Sonia ^b   Crucil, Ilaria ^b   Sava, Gianni ^b   Scarlata, Ignazio ^b   Cantoni, Silvia ^b   Fedeli, Maya ^a   Coradini, Danila ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Butyric acid; CD44; Histone deacetylase inhibitor; Hyaluronic acid; Pancreatic cancer

Indexed keywords

BUTYRIC ACID; CASPASE 7; CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HERMES ANTIGEN; HISTONE DEACETYLASE INHIBITOR; HYALURONIC ACID DERIVATIVE; HYALURONIC BUTYRIC ESTER; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SURAMIN; SURVIVIN; VASCULOTROPIN 165; VASCULOTROPIN C; VASCULOTROPIN D;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; ESTERIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BUTYRATES; BUTYRIC ACIDS; CELL CYCLE; CELL DIVISION; CELL LINE; HUMANS; HYALURONIC ACID; KINETICS; PANCREAS; PANCREATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 42549115689     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31816705bc     Document Type: Article

References (42)

1. Rosenberg L. Pancreatic cancer: a review of emerging therapies. Drugs. 2000;59:1071-1089.
2. Warshaw AL, Fernandez-Del Castello C. Pancreatic carcinoma. N Engl J Med. 1992;326:455-465.
3. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
4. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20:3270-3275.
5. Csordas A. The biological role of histone acetylation. Biochem J. 1990;265:23-38.
6. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 1996;5:245-253.
7. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000;92:1210-1216.
8. Zhang JS, Wang L, Huang H, et al. Keratin 23 (K23), a novel acidic keratin, is highly induced by histone deacetylase inhibitors during differentiation of pancreatic cancer cells. Genes Chromosomes Cancer. 2001;30:123-135.
9. Mullins TD, Kern HF, Metzgar RS. Ultrastructural differentiation of sodium butyrate-treated human pancreatic adenocarcinoma cell lines. Pancreas. 1991;6:578-587.
10. Pellizzaro C, Coradini D, Daidone MG. Modulation of angiogenesis-related proteins synthesis by sodium butyrate in colon cancer cell line HT29. Carcinogenesis. 2002;23:735-740.
11. Williams RJ. Trichostatin A, an inhibitor of histone deacetylase, inhibits hypoxia-induced angiogenesis. Expert Opin Invest Drugs. 2001;10:1571-1573.
12. Sealy L, Chalkley R. The effect of sodium butyrate on histone modification. Cell. 1978;14:115-121.
13. Daniel P, Brazier M, Cerrutti I, et al. Pharmacokinetic study of butyric acid administrated in vivo as sodium arginine butyrate salt. Clin Chim Acta. 1989;181:255-263.
14. Rudzki Z, Jothy S. CD44 and adhesion of neoplastic cells. J Clin Pathol Mol Pathol. 1997;50:57-71.
15. Takada M, Yamamoto M, Saitoh Y. The significance of CD44 in human pancreatic cancer: I. High expression of CD44 in human pancreatic adenocarcinoma. Pancreas. 1994;9:748-752.
16. Coradini D, Pellizzaro C, Abolafio G, et al. Hyaluronic-acid butyric ester as promising antineoplastic agents in human lung carcinoma: a preclinical study. Invest New Drugs. 2004;22:207-217.
17. Coradini D, Zorzet S, Rossin R, et al. Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin Cancer Res. 2004;10:4822-4830.
18. Hamel PA, Hanley-Hide J. G1 cyclins and control of the cell division cycle in normal and transformed cells. Cancer Invest. 1997;15:143-146.
19. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell cycle control causing a specific inhibition of cyclin D/cdk4. Nature. 1993;366:704-706.
20. Li Y, Jenkins CW, Nichols MA, et al. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene. 1994;9:2261-2268.
21. Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry. 2001;40:1117-1123.
22. Willis S, Day CL, Hinds MG, et al. The Bcl-2-regulated apoptotic pathway. J Cell Sci. 2003;116:4053-4056.
23. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
24. Stacker SA, Baldwin ME, Achen MG. The role of tumor lymphoangiogenesis in metastatic spread. FASEB J. 2002;16:922-934.
25. Giuliani N, Colla S, Lazzaretti M, et al. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood. 2003;102:638-645.
26. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
27. He Y, Karpanen T, Alitalo K. Role of lymphoangiogenic factors in tumor metastasis. Biochem Biophys Acta. 2004;1654:3-12.
28. Twentyman PR, Luscombe M. A study of same variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer. 1987;56:279-285.
29. Liao HX, Lee DM, Levesque MC, et al. N-terminal and central regions of the human CD44 extracellular domain participate in cell surface hyaluronan binding. J Immunol. 1995;155:3938-3945.
30. Pellizzaro C, Coradini D, Abolafio G, et al. Modulation of cell cycle-related proteins but not of p53 expression by sodium butyrate in human non-small cell lung cancer cell line. Int J Cancer. 2001;91:658-664.
31. Kumar S, Witzig TE, Timm M, et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favouring loss of marrow angiogenesis inhibitory. Blood. 2004;104:1159-1165.
32. Rosenberg L, Lipsett M. Biotherapeutic approaches to pancreatic cancer. Expert Opin Biol Ther. 2003;3:319-337.
33. Sowa Y, Orita T, Minamikawa S, et al. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the SP1 sites. Biochem Biophys Res Commun. 1997;241:142-150.
34. Xiao H, Hasegawa T, Isobe K. p300 collaborates with SP1 and SP3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor. J Biol Chem. 2000;275:1371-1376.
35. Cip1/Waf1 at both the G1/S and G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol. 1998;18:629-643.
36. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501-1512.
37. Li F. Survivin study: what is the next wave? J Cell Physiol. 2003;197:8-29.
38. Satoh K, Kaneko K, Hirota M, et al. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer. 2001;92:271-278.
39. Folkman J. Tumor angiogenesis: therapeutic implication. N Engl J Med. 1971;285:1182-1186.
40. Kim KJ, Li B, Armanini M, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841-844.
41. Bocci G, Danesi R, Benelli U, et al. Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo. Cancer Chemother Pharmacol. 1999;43:205-212.
42. Coradini D, Pellizzaro C, Scarlata I, et al. A novel retinoic/butyric hyaluronan ester for the treatment of acute promyelocytic leukemia: preliminary preclinical results. Leukemia. 2006;20:785-792.